Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Cytoplasmic poly(A)-binding protein 1 (PABPC1) is a prognostic biomarker to predict survival in nasopharyngeal carcinoma regardless of chemoradiotherapy

Fig. 3

The Kaplan–Meier survival analysis according to regimens. The overall survival (OS) (a) and disease-free survival (DFS) (d) of treated patients were significantly better than those of the untreated; Patients with PABPC1 low expression had significantly better OS but not DFS than those with PABPC1 high expression in the treated group (b and e); In contrast, patients with PABPC1 low-expression had significantly better OS and DFS in the untreated group (c and f); There was no difference for OS (g) or DFS (j) among the patients with paclitaxel/docetaxel-based IC + CCRT, the patients with CCRT, and the patients with IMRT only; There was no difference for OS (h) or DFS (k) between patients with paclitaxel-based IC + CCRT and patients with docetaxel-based IC + CCRT; OS (i) but not DFS (l); Patients with paclitaxel-based IC + CCRT and PABPC1 low-expression was significantly better than those with other chemoradiotherapy regimens

Back to article page